We've scheduled your Type T meeting with FDA commish Scott Gottlieb, where you can learn the art of rapid fire R&D
Here we’re introducing the Type T(witter) meeting with the head of the FDA on streamlined drug development.
Anybody who’s been paying attention to our surveys of the Endpoints 100 would not be surprised to learn that a large majority of biotech execs have a big crush on FDA commissioner Scott Gottlieb. One big reason for the love affair between the industry and the commish is that from the execs’ perspective Gottlieb’s pushing to make the agency far more responsive to criticism and the need to batter down some longstanding hurdles in the way of drug developers. And they want it done without tossing the gold standard of R&D out the window and making it a free-for-all.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.